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ABSTRACT
Species of Candida and Aspergillus remain the most common causes of invasive fungal infections, but
other yeasts and filamentous fungi are emerging as significant pathogens. Opportunistic yeast-like fungi
and moulds such as Zygomycetes, Fusarium spp. and Scedosporium spp. are increasingly being
recognised in patient groups such as those with leukaemia and in bone marrow transplant recipients.
Recognition of these epidemiological changes is critical to patient care. The key elements in selecting an
appropriate antifungal agent are the type of patient (solid-organ or stem-cell transplant), severity of
immunosuppression, history of prolonged exposure to antifungal drugs, and knowledge of the genera
and species of the infecting pathogen and its typical susceptibility pattern.
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INTRODUCTION
Invasive fungal infections are increasingly com-
mon in the nosocomial setting. [1–5]. Furthermore,
because risk-factors for these infections continue
to increase in frequency, it is likely that the
incidence of nosocomial fungal infections will
continue to increase in the coming decades. This
expansion is based on an increase in the number of
immunocompromised patients, including cancer
patients with chemotherapy-induced neutropenia,
transplant recipients receiving immunosuppres-
sive therapy, and human immunodeficiency virus
(HIV)-infected patients [6–9]. Better control of
underlying diseases and improved antimicrobial
therapies result in prolonged survival, thus putt-
ing these patients at higher risk of acquiring an
opportunistic fungal infection. The predominant
nosocomial fungal pathogens include Candida
spp., Aspergillus spp., Mucorales, Fusarium spp.,
and other moulds, including Scedosporium spp.
[1,10–12]. These infections are difficult to diagnose
and cause high rates of morbidity and mortality,
despite antifungal therapy. Early initiation of
effective antifungal therapy and reversal of under-
lying host defects remain the cornerstones of
treatment for nosocomial fungal infections. In
recent years, new antifungal agents have become
available, resulting in a change in the standard of
care for many of these infections. Nevertheless, the
mortality rate of nosocomial fungal infections
remains high, and new therapeutic and preventive
strategies are needed. In the USA, the estimated
annual incidences of invasive Candida and Asper-
gillus infections are 72–228 and 12–34 infections
per million population, respectively [10,13,14]. At
this time, we face a marked shift in the epidemi-
ological profile of fungal infections: new and
emerging pathogens such as Zygomycetes (e.g.,
Rhizopus and Mucor spp.), hyaline moulds (e.g.,
Fusarium spp.), yeast-like fungi (e.g., Trichosporon
spp.) and some dematiaceous fungi are increas-
ingly being reported (Table 1). This article reviews
selected aspects of the epidemiological profiles of
invasive mycoses, risk-factors for infections and
the susceptibility to antifungal agents.
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MEDICALLY IMPORTANT YEASTS
AND YEAST-LIKE FUNGI
Candida
Bloodstream infections (BSIs) due to Candida spp.
have become common in both adult and paediatric
intensive care units (ICUs), accounting for 10–15%
of hospital-acquired BSIs. This rising incidence
has been attributed to several risk-factors that are
prevalent in critically ill patients, such as debility,
underlying malignancy, blood and bone marrow
transplantation, AIDS, prolonged ICU and hospi-
tal stay, neutropenia, use of antibiotics and corti-
costeroids, and administration of parenteral
alimentation. In most cases, the yeast’s portal of
entry is the gut, but in other patients, especially
those with central venous catheters (CVCs), the
skin is the most likely culprit. Candidaemia may
occur in both immunocompromised and non-
immunocompromised patients. The development
of candidaemia, however, strongly implies
immunodeficiency, since it often occurs in immu-
nocompromised patients, and more specifically,
in 10–20% of those with myeloproliferative dis-
orders or leukaemia and in up to 74% of patients
with AIDS.
An increasing incidence has been observed for
all clinical manifestations, including oropharyn-
geal infections, post-operative site infections, and
urinary tract infections, but is especially dramatic
for candidaemia. This rising incidence of Candida
infections and candidaemia can be attributed to a
variety of mostly endogenous and exogenous
factors. Granulocytopenia is the most important
risk-factor for the development of systemic candi-
dosis in patients with cancer. The improved and
intensified treatment of patients with cancer
induces granulocytopenia of significantly long
duration. Damage to the oropharygeal mucosa
through the use of aggressive cytostatic drugs
facilitates Candida colonisation and subsequent
invasion.
One of the most important groups of opportu-
nistic fungal pathogens comprises Candida spp.
[2,10,11,15–19], which account for 8–10% of all
nosocomial BSIs and remain important pathogens
in ICUs [20]. Invasive infections are associated
with an attributable mortality rate of 10–49%, an
excess duration of hospital stay and an enormous
excess of costs [21]. Although some centres report
an increased mortality rate associated with spe-
cies of Candida other than Candida albicans as
compared with C. albicans, no consistent pattern
has emerged.
More than 100 species are known, with C. albi-
cans being the main representative. The frequency
of Candida spp. distribution varies according to
the geographical setting [3,15,22,23]: 44% and
62% of BSIs due to C. albicans were documented
in Latin America and in Europe, respectively.
Nearly 95% of episodes of candidaemia are
caused by C. albicans, Candida glabrata, Candida
parapsilosis, Candida tropicalis and Candida krusei
[3,4,10,11]. C. albicans infections occur less
Table 1. Spectrum of opportunistic
fungal pathogensaCandida spp. C. albicans Other yeasts Blastoschizomyces spp.
C. glabrata Cryptococcus neoformans
C. gulliermondii Malassezia spp.
C. kefyr Rhodotorula spp.
C. krusei Saccharomyces spp.
C. lusitaniae Trichosporon spp.
C. rugosa Zygomycetes Absidia spp.
C. parapsilosis Cunninghamella spp.
C. tropicalis Mucor spp.
Aspergillus spp. A. fumigtus Rhizomucor spp.
A. niger Rhizopus spp.
A. flavus Dematiaceous
moulds
Alternaria spp.
A. terreus Bipolaris spp.
Other hyaline
moulds
Acremonium spp. Curvularia spp.
Fusarium spp. Cladophialophora spp.
Paecilomyces spp. Exophiala spp.
Scedosporium spp. Phialophora spp.
Scopulariopsis spp.
Trichoderma spp.
aAdapted from reference [109].
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frequently with increasing patient age [2], after
exposure to azole antifungals [22], and in the ICU
setting [3]. Since the 1990s, fluconazole has been
widely used for prophylaxis and treatment of
invasive fungal infections in immunocompro-
mised patients; this resulted in a decreased
incidence of BSIs worldwide [16,24,25], but an
increased incidence of C. glabrata and other non-
albicans Candida infections. C. glabrata is emerging,
and accounts for 20% of BSIs in the USA (12–
37%), 15% in Europe, 10% in Asia, and 5% in
Latin America [26]. The reason for the occurrence
of C. glabrata appears to be multifactorial [26,27],
and includes geographical characteristics [23,26],
age [27], patient populations [16,22] and use of
fluconazole [16,22]. C. parapsilosis is the second
most common species recovered from blood
cultures in Europe [28] and tends to form biofilms
on the surface and lumens of catheters [29,30];
biofilm-producing microbes may be completely
resistant to antifungals [29]. C. parapsilosis has
also been known to colonise the hands of health-
care workers, thus emphasising the importance of
hand hygiene and proper catheter care. This
species is most common in neonates and children,
and is associated with a lower mortality rate.
C. parapsilosis isolates can be divided into three
groups on the basis of molecular studies [31,32].
Two new species, Candida orthopsilosis and Can-
dida metapsilosis, are proposed to replace the
existing designations of C. parapsilosis groups II
and III, respectively. The species name C. parapsi-
losis is retained for group I isolates. None of the
clinical C. orthopsilosis isolates were found to
produce biofilm in vitro.
C. tropicalis is known to be an important cause
of infections in patients with cancer [16,22] and
appears to be more virulent than C. albicans in
patients with haematological malignancy. Dis-
semination is associated with high mortality rates.
In a retrospective survey of candidaemia
performed at the University Hospital Vienna
between 2001 and 2006, the number of non-
C. albicans infections increased, with C. tropicalis
causing 7% [33]. Most infections appear to orig-
inate from the patients’ endogenous microflora.
An outbreak of C. tropicalis sternal wound infec-
tions following cardiac surgery was traced to a
colonised scrub nurse [34]. Most C. tropicalis
strains are susceptible to amphotericin B, flucyto-
sine, and triazoles [35]. Paradoxical growth of
C. tropicalis strains was noted in RPMI-1640 and
antibiotic medium three at caspofungin concen-
trations of 12.5 mg ⁄L [36].
C. krusei is a fluconazole-resistant species and is
an uncommon cause of candidaemia (<3%) [36].
However, the emergence of C. krusei may have a
profound effect on clinical outcome. A compara-
tive study of fungaemia in immunocompromised
patients showed the mortality rate associated
with C. krusei to be 49%, as compared to a rate
of only 28% with C. albicans. Antifungal response
rates are also lower with C. krusei, although
amphotericin B achieves a success rate of 51%
[37]. Endogenous spread from the gastrointestinal
tract is the main mechanism of infection, partic-
ularly in patients with haematological malignancy
[38]. Several reports have described an increase in
C. krusei colonisation and infection in granulocy-
topenic patients that was associated with use of
fluconazole as prophylaxis.
Candida lusitaniae is an important cause of
nosocomial infection among immunocompro-
mised hosts. It is an endogenous pathogen but
nosocomial transmission can occur. Initial resis-
tance or rapid development of resistance to
amphotericin B is characteristic of this species.
Most strains are susceptible to azoles. Colony
morphology switching of C. lusitaniae might be
associated with the acquisition of multidrug
resistance in this species [39].
Candida rugosa is a fungus that appears to be
emerging as a cause of infection in some geo-
graphical regions. Pfaller et al. [40] observed
geographical and temporal trends; C. rugosa
accounted for 0.4% of Candida spp. and the
frequency of isolation increased from 0.03% to
0.4% between 1997 and 2003. C. rugosa was most
common in the Latin American region (2.7%),
and 40.5% of strains were susceptible to fluco-
nazole. Isolates from Europe and North America
were much more susceptible (97–100%) to vori-
conazole than those from other geographical
regions (55.8–58.8%). Bloodstream isolates were
the least susceptible to both fluconazole and
voriconazole.
Factors associated with an increased risk of
invasive candidosis are shown in Table 2. Candi-
daemia was found to be an independent risk-
factor for death during hospitalisation [41], and
the outcome depended on early administration of
adequate therapy [21].
Antifungal prophylaxis has been proven to
decrease invasive candidosis in neutropenic
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patients [16]. The data are less compelling for
non-neutropenic ICU patients. Initial treatment
should be guided by combining the local epide-
miology and the most important risk-factors.
Usually, C. albicans, C. parapsilosis and C. tropicalis
are susceptible to polyenes, the azoles and the
echinocandins (Table 3). C. glabrata is inherently
less susceptible to fluconazole, and C. krusei is
intrinsically resistant to fluconazole [42].
A particular problem with patients with candi-
daemia and invasive candidosis is that they are
difficult to distinguish clinically from patients
with bacterial sepsis, at least early in infection.
This often leads to an initial delay in instituting
antifungal therapy, and furthermore the choice of
initial empirical therapy may be inappropriate.
Parkins and colleagues investigated the relation-
ship between the adequacy of initial empirical
antifungal therapy and outcome of bloodstream
and invasive Candida infections by reviewing 207
patients who had an invasive Candida infection
over a 5-year period [43]. Only one-third of
patients received empirical antifungal therapy,
and furthermore, the therapy was deemed appro-
priate in 26% of patients. Crucially, the authors
were able to demonstrate that adequate empirical
therapy was associated with a significant reduc-
tion in mortality from 46% to 27%. Notably, in
this study, around half of the infections were
demonstrated to be due to species of Candida
other than C. albicans, with 22% being due to
C. glabrata alone.
Opportunist yeast-like fungi
Trichosporon
Trichosporon spp. are normal residents of human
skin and can be isolated from soil and water.
Table 2. Co-morbid conditions for candidaemia in
hospitalised patients
Underlying factorsa
Broad-spectrum antimicrobial agents (number and
duration)
Steroids (therapy and prophylaxis)
Extremes of age (<1 and >70 years)
Chemotherapy
Malignancy
Previous colonisation (‡2 sites)
Gastric acid suppression
Indwelling catheter (CVC, Hickmann catheter)
Total parenteral nutrition
Neutropenia (<500 ⁄mm3)
Surgery (gastrointestinal) or gastrointestinal damage
Mechanical ventilation
Any renal failure (haemodialysis)
Malnutrition
ICU stay (>10 days), >APACHE II score
Severity of disease
Mucositis
GvHD (acute and chronic)
Stem-cell and organ transplant
CVC, central venous catheter; ICU, intensive care unit;
GvHD, graft vs. host disease.
aData compiled from references [3,4,9,12,13,19,20,25,110–
116].
Table 3. In-vitro susceptibility data
for Candida spp. commonly associ-
ated with bloodstream infectionsa
Candida spp.
Susceptibilityb
AMB 5-FC FLU ITR VOR POS CAS
C. albicans S S S S S S S
C. glabrata S-I S S-SDD-R S-SDD-R S-I S S
C. krusei S R R S-SDD-R S-I S S
C. lusitaniae S-R S S S S S S
C. parapsilosis S S S S S S S-I
C. tropicalis S S S S S S S
S, susceptible; I, intermediate (susceptibility is not certain); SDD, sensitive dose-
dependent; AMB, amphotericin B; 5-FL, flucytosine; FLU, fluconazole; ITR,
itraconazole; VOR, voriconazole; POS, posaconazole; CAS, cancidas.
aData adapted from references [2,13,23,112,117,118].
bThe CLSI has established interpretative breakpoints for Candida spp. tested
against fluconzole, itraconazole and flucytosine using CLSI-recommended
guidelines for broth dilution testing. On the basis of these breakpoints, resistance
is defined as MIC of >64 mg ⁄L for FLU, >1 mg ⁄L for ITR and >32 mg ⁄L for 5-FU.
For the purposes of this table, susceptible is defined as MIC <1 mg ⁄L of AMB,
CAS, VOR and POS.
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Eight species of Trichosporon are known human
pathogens, with Trichosporon asahii and Trichospo-
ron mucoides accounting for the majority of deep-
seated and disseminated infections. Risk-factors
for infection include immunosuppression, disrup-
tion of mucosal integrity, and CVCs. A major
risk-factor for trichosporonosis is underlying hae-
matological malignancy. In a review by Girmenia
et al. [44], 63% of 287 Trichosporon cases had an
underlying haematological malignancy. Those at
greatest risk include neutropenic cancer patients
receiving cytotoxic treatment. Less commonly,
disseminated infection has been seen in solid-
organ transplant recipients, burn patients, low-
birth-weight infants, and persons with AIDS.
Factors that enhance mucosal colonisation and
subsequent invasive infection include broad-spec-
trum antibiotic treatment and breaks in anatom-
ical barriers. The overall mortality rate is high,
ranging from 60% to 80% in earlier reports. Some
improvement has been achieved with recent
developments in diagnosis, treatment and pre-
vention. Isolates of T. asahii are often resistant to
amphotericin B in vitro.
The optimal antifungal treatment for trichosp-
oronosis is currently unclear, and despite anti-
fungal therapy, the prognosis is poor, with over
three-quarters of patients dying. Echinocandins
have poor activity against Trichosporon spp. and,
indeed, breakthrough cases in patients receiving
micafungin and caspofungin have been reported
[45,46]. Azole antifungals seem to be more potent
than amphotericin B, and the newer triazoles,
voriconazole, posaconazole, and ravuconazole,
appear to be active in vitro. Successful treatment
of trichosporonosis with triazoles has been re-
ported [47].
Rhodotorula
Rhodotorula spp. have increasingly been recogni-
sed as important human pathogens. Immuno-
conmpromised patients, particularly those with
CVSs or other indwelling devices, are at highest
risk for infection. While Rhodotorula strains
appear to be less virulent than the more common
yeast pathogens such as Candida, Rhodotorula
infection has been associated with a crude mor-
tality rate of up to 15% and can cause sepsis
syndrome and other life-threatening complica-
tions. Rhodotorula BSIs have been successfully
managed with line removal alone, antifungal
therapy with line removal, and a combination of
these approaches. In a recent review by Tuon
et al. [48], where all cases of CVC-related funga-
emia due to Rhotorula spp. reported in the
literature were considered, it was found that all
patients but one in the 88 cases examined had
some form of underlying disease, including 69
(78.4%) who had cancer. Rhodotorula mucilaginosa
was the species most frequently recovered (75%),
followed by Rhodotorula glutinis (6%). Amphoter-
icin B deoxycholate was the most common anti-
fungal agent used as treatment, and the overall
mortality rate was 9.1%. The authors conclude by
stressing that fungaemia caused by Rhodotorula is
rare but is increasingly seen in immunocompro-
mised and in ICU patients. Additionally, it is
noted that Rhodotorula spp. are resistant to fluco-
nazole. Recent in-vitro data extend our under-
standing of antifungal activity against Rhodotorula
spp. [49]. Here, the activities of eight antifungals
against 64 Rhodotorula isolates collected in sur-
veillance programmes between 1987 and 2003
were determined. The strains were resistant
in vitro to fluconazole (MIC50, >128 mg ⁄L) and
caspofungin (MIC50, >8 mg ⁄L). Amphotericin B
(MIC50, 1 mg ⁄L) and flucytosine (MIC50,
0.12 mg ⁄L) were both active in vitro, and the
new and investigational triazoles all had some in-
vitro activity, with ravuconazole being the most
active (MIC50, 0.25 mg ⁄L).
Geotrichum capitatum
G. capitatum, formerly known as Trichosporon
capitatum or Blastoschizomyces capitatus, is an
uncommon, but frequently fatal, cause of invasive
infections in immunocompromised patients, par-
ticularly those with haematological malignancies
[44]. In a recent retrospective multicentre study
from Italy, the incidence of G. capitatum infection
among patients with acute leukaemia was 0.5%,
with a 55.7% crude mortality rate [44]. G. capit-
atum is susceptible to amphotericin B and azoles,
in particular voriconazole, but is intrinsically
resistant to echinocandins [44]. This is exempli-
fied in a further series of three patients from the
same authors, where it was shown that, in one
patient, infection improved when caspofungin
was replaced by voriconazole [50]. In a second
patient, a breakthrough G. capitatum infection
developed while the patient was undergoing
antifungal prophylaxis with caspofungin; and in
the third patient, the choice of voriconazole
therapy was based on the observation of multiple
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maculo-papular skin lesions suggestive of dis-
seminated Candida infection.
Pichia (Hansenula)
The main species implicated in human infections
are Pichia anomala (previously Hansenula anomala)
and Pichia angusta (previously Hansenula polymor-
pha). Recently, there was a report of P. angusta
and P. anomala being responsible for cases of
fungaemia in a Brazilian paediatric ICU [51]. The
source of the infection was never found. Patients
with P. anomala fungaemia seem to have
risk-factors in common with those who have
candidaemia. A number of transient cases of
candidaemia caused by Candida utilis (Pichia
jadinii) have been reported.
Debaromyces
Debaromyces hansenii is the anamorph form of
Candida famata. C. famata has been repeatedly
associated with catheter-related BSIs, and occa-
sionally with infections of the central nervous
system. The reservoir of C. famata is not known,
but there is a possibility that nosocomial infec-
tions can occur via air contamination [52]. No
studies on the antifungal susceptibility of Debary-
omyces are available.
Klyveromyces
Candida kefyr, the anamorph of Klyveromyces
marxianus, has occasionally been involved in
opportunistic infections in immunocompromised
persons. Klyveromyces is found on certain food-
stuffs (mainly dairy products). The collective
experience at three particular French hospitals
exemplifies the apparent emergence of C. kefyr
colonisation in patients with onco-haematological
diseases [53]. During a 6-year period (2000–2005),
64 417 isolates of Candida spp. were collected
from three French teaching hospitals with 4150
beds, including 305 onco-haematological unit
beds. In total, 12 834 (20%) of 64 417 Candida
isolates were recovered from patients hospitalised
in onco-haematology wards. C. kefyr was isolated
twice as often from patients in onco-haematology
wards as from those hospitalised in other wards
(4.8% vs. 1.9%; p <0.001). Among the 1604
C. kefyr isolates recovered during this period,
623 (38.8%) were isolated from patients in
onco-haematology wards (p <0.001). During the
same period, ten patients developed a C. kefyr
BSI, of whom nine (90%) were hospitalised in
onco-haematology wards. Most patients (seven of
nine) had myeloid or lymphoblastic leukaemia.
The reasons why C. kefyr is an emergent yeast in
the fungal flora of neutropenic patients are not
known, because the gastrointestinal yeast flora of
healthy individuals is composed mainly of C. albi-
cans and C. glabrata. Even though C. kefyr is found
on certain foodstuffs (mainly dairy products), it is
not known why this yeast is isolated more
frequently from patients with onco-haematologi-
cal diseases. It can be hypothesised that: (i) the
use of empirical therapeutics as well as antifungal
prophylaxis could induce selection of C. kefyr in
the gastrointestinal flora, because some strains of
C. kefyr have high MICs against amphotericin B;
and (ii) colonisation of neutropenic patients with
C. kefyr could be favoured by modifications in
gastrointestinal homeostasis, in particular by the
induction of mucositis by antimycotics (i.e. mu-
cositis could favour colonisation by C. kefyr).
Saccharomyces cerevisiae
S. cerevisiae (also known as ‘baker’s yeast’ or
‘brewer’s yeast’) is mostly considered to be an
occasional digestive commensal. However, since
the 1990s, there have been a growing number of
reports about its involvement as an aetiological
agent of invasive infection in ‘fragile’ populations.
A particular feature of such infections is their
association with a probiotic preparation of S. ce-
revisiae (subtype Saccharomyces boulardii) for treat-
ment of various diarrhoeal disorders (see below).
The nature of S. cerevisiae (subtype S. boulardii)
and its clinical applications have been recently
reviewed [54,55].
In a recent clinical review, 92 cases of Sac-
charomyces invasive infection were presented,
only 15 of which were diagnosed before 1990
[56]. All patients had at least one condition
facilitating the opportunistic development of
S. cerevisiae infections. Predisposing factors were
similar to those of invasive candidosis, with
intravascular and antibiotic therapy being the
most frequent. Blood was the most frequent site
of isolation (78%, or 72 patients). S. cerevisiae
(subtype S. boulardii) accounted for 51.3% (47
cases) of fungaemias, and was exclusively iso-
lated from blood.
There are several additional reports and
reviews regarding the safety of S. cerevisiae (sub-
type S. boulardii) probiotic preparations. For
example, there have been cases of acquired
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S. cerevisiae fungaemia [57,58]. The authors con-
cluded that probiotics should be used cautiously
in certain high-risk populations. A review of the
current literature reinforces the view that funga-
emia and sepsis are rare complications of the
administration of S. cerevisiae (subtype S. boular-
dii) in immunocompromised patients but con-
firms that the most important risk-factor for
S. cerevisiae fungaemia is the use of probiotics
[59,60]. This raises the question of the risk ⁄ benefit
ratio of these agents in critically ill or immuno-
compromised patients, who are likely to develop
an infection after exposure to high amounts of a
microorganism with low virulence.
Cryptococcus
Cryptococcal infections occur with a near world-
wide distribution in immunosuppressed hosts.
Infection is typically caused by Cryptococcus neo-
formans, an encapsulated yeast, and infection is
acquired from the environment. The organism
lives in soil and organic matter containing high
concentrations of pigeon and bird excreta. C. neo-
formans is neurotropic, and most patients with
cryptococcal meningitis suffer from a defect in
cellular immunity. The infection is seen most
frequently in association with lymphoma, AIDS,
transplantation, and corticosteroid therapy [61].
In a recent review of cryptococcal infection in
HIV-negative patients, splenectomy was reported
to be a risk-factor for infection in 3% of cases [62].
Non-neoformans cryptococci have been generally
regarded as saprophytes and rarely reported as
human pathogens [63]. However, the incidence of
infection due to these organisms has increased
over the past 40 years, with Cryptococcus laurentii
and Cryptococcus albidus, together, being respon-
sible for 80% of reported cases. Conditions
associated with impaired cell-mediated immunity
are important risk-factors for non-neoformans
cryptococcal infections, and prior azole prophy-
laxis has been associated with resistance. Crypto-
coccus gattii causes disease in immunocompetent
people in a geographically restricted area in
Australia [64]. It is notable that there are invasive
C. gattii infections in immunocompetent humans
on Vancouver Island, western Canada [65,66]. The
organism, which is thought to thrive only in
tropical regions, was recovered in the temperate
climatic zone. It has been postulated that envi-
ronmental factors may support its propagation.
PATHOGENIC FILAMENTOUS FUNGI
Aspergillus
In general, the clinical significance of filamentous
fungi can be inferred from the following data. In
Europe, c. 18 000 patients will be diagnosed with
acute leukaemia alone, and c. 13 000 will die of
this disease each year. It is estimated that approx-
imately 99 000 patients will be treated for a
haematological malignancy, and that c. 18 800
will undergo a bone marrow or organ transplant.
Significant proportions of the patients undergoing
lung or allogenic bone marrow transplantation
and of the patients with acute leukaemia will
develop invasive mycoses. Roughly estimated,
5000–6000 cases involve filamentous fungi, which
mostly become the ultimate cause of death.
Aspergillus spp. are opportunistic moulds that
cause both allergic and invasive syndromes. The
genus Aspergillus contains approximately 175
species, but only a minority of them have been
associated with human disease. Infections are
caused mostly by Aspergillus fumigatus, followed
by Aspergillus flavus, Aspergillus terreus, Aspergillus
niger and Aspergillus nidulans. Aspergillus is found
in soil, water, food, and the air, and grows on a
wide variety of organic material, such as decaying
vegetation. The conidia (spores) are easily aeros-
olised. The route of transmission is via the air.
Although exposure is universal, invasive infection
occurs almost exclusively in immunocompro-
mised individuals. Infections have frequently
been described in patients with haematological
malignancies and solid-organ transplant recipi-
ents, and also in patients undergoing chronic
intermittent haemodialysis, in whom these infec-
tions were associated with hospital construction
and ⁄ or ventilation systems contaminated with
Aspergillus spp. Even hospital water is a fre-
quently overlooked source of nosocomial asper-
gillosis.
Aspergillus spp. are common throughout the
world and are ubiquitous in air, soil, and decay-
ing matter [67]. Invasive aspergillosis (IA) has
emerged as a leading cause of morbidity and
mortality in immunocompromised patients [68].
A. fumigatus is most frequently isolated from
cases of IA, followed by A. flavus, A. niger, and
A. terreus [69,70]. A. terreus has been recognised as
a cause of frequently lethal infections [71,72]. In
certain hospitals, A. flavus is more common than
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A. fumigatus, and the reasons for increased num-
bers of non-A. fumigatus infections are not fully
elucidated [73]. Outbreaks associated with A. fla-
vus appear to be associated with single or closely
related strains, in contrast to those associated with
A. fumigatus. Common clinical syndromes associ-
ated with A. flavus include chronic granuloma-
tous sinusitis, keratitis, cutaneous aspergillosis,
wound infections and osteomyelitis following
trauma and inoculation. In addition, A. flavus
produces aflatoxins, the most toxic and potent
hepatocarcinogenic natural compounds ever char-
acterised. The flavus complex currently includes
23 species or varieties, including two sexual
species, Petromyces alliaceus and Petromyces albert-
ensis.
Infections caused by a recently recognised new
species of Aspergillus have been reported [74,75].
The organism, which, according to classic mor-
phological typing methods, is typically identified
as A. fumigatus, clusters as a unique species with
multilocus sequence typing, supporting the pro-
posed designation of Aspergillus lentulus (Balajee
2005). The organism may be of particular interest
because isolates exhibit low susceptibility to
multiple antifungals in vitro.
Many factors, such as unique environmental
exposure, specific host-related characteristics
(e.g., chronic obstructive pulmonary disease
(COPD), chronic granulomatous disease (CGD),
cystic fibrosis (CF)), and the net state of immu-
nosuppression of the affected patients, may par-
tially account for this trend [5,76–80]. Overall, the
outcome of infection appears to depend more on
host factors than on the virulence or pathogenicity
of the individual Aspergillus species. Studies
including stem-cell and solid-organ transplant
recipients revealed Aspergillus spp. to be the
predominant moulds, followed by zygomycetes,
and fusarium [81]. Solid-organ transplant recipi-
ents were more likely to develop candidosis,
whereas stem-cell transplant recipients were at
higher risk for moulds [63]. More than 60% of
patients with IA have underlying haematological
diseases or have undergone bone marrow trans-
plantation [45,78]. Recovery of Aspergillus spp.
from the respiratory tract secretions of ICU
patients should be considered as a marker of
infection [82]. Similar findings are made in
patients with haematological malignancies [80].
Multiple analyses have identified patients at
high risk (Table 4). IA is associated with a high
mortality rate of 65% [45,79,80]. In-vitro suscep-
tibility testing is not routinely recommended, but
may be useful when the infection fails to respond.
The vast majority of Aspergillus spp. remain
susceptible to the various antifungal agents
(Table 5).
Several recent reviews have highlighted the
increasing incidence of invasive Aspergillus infec-
tions that are associated with critical care medi-
cine [82–84]. Critically ill patients undergoing
intensive care exhibit a complex change in
immune function, characterised by deactivation
of macrophages and an altered cellular response
due to the severity of illness, which is also termed
‘immunoparalysis’. This immunological derange-
ment might explain why Aspergillus infections are
able to develop in critically ill patients who do not
display the predisposing classic risk-factors.
Many other factors will negatively influence
immune function during critical illness, such as
(acute) hyperglycaemia and the use of corticos-
teroids. Corticosteroids have profound effects on
the distribution and function of neutrophils,
Table 4. Co-morbid conditions for aspergillosis and
mould infections in patients at riska
Haematological
malignancies Organ transplant patients
Leukaemia Lung, liver, heart, renal
Myelodysplastic syndrome Acute and chronic rejection
Stem-cell transplant Steroids
GvHD (acute and chronic) Haemodialysis
Prolonged neutropenia Tacrolimus
Induction chemotherapy OKT 3
Fungal colonisation Renal failure
Local epidemiology Cytomegalo virus (CMV)
Steroid prophylaxis Re-transplantation
Neutrophil dysfunction Splenectomy
Cytotoxic drugs Alemtuzumab
Infliximab Local epidemiology
Alemtuzumab Diabetic ketoacidosisb
T-cell-depleted stem-cell
products
Iron overloadb
Diabetes mellitusb
CD34-selected stem-cell
products
Deferoxamine therapyb
Skin breakdownb
Diabetic ketoacidosisb
Iron overloadb
Diabetes mellitusb
Deferoxamine therapyb
Skin breakdownb
GvHD, graft vs. host disease.
aData compiled from references [6,9,20,110,111,113,114,
119–124].
bRelated to zygomycosis.
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monocytes, and lymphocytes, and they directly
stimulate the growth of A. fumigatus in vitro,
possibly via sterol-binding proteins in the fungus.
In particular, intravenous corticosteroid treatment
in patients with COPD is associated with a rising
incidence of IA [84]. Also, broad-spectrum anti-
biotics, which affect the distribution of the normal
flora, have been described as a risk-factor [84].
However, not every critically ill patient in the ICU
is at risk of developing invasive fungal infections.
Apparently, other specific—patient-related—pre-
disposing conditions seem to be associated with
the development of IA; COPD and other chronic
lung diseases, diabetes mellitus, acute liver fail-
ure ⁄ advanced liver cirrhosis, chronic renal failure
and near-drowning have been described. In these,
mainly retrospective, studies, a mean in-hospital
mortality rate of 80% was found in patients with
highly suspected or proven IA in the presence of
at least one of these underlying conditions,
despite antifungal therapy. Remarkably, patients
who were suspected of being colonised only with
Aspergillus spp. (i.e., no signs of pulmonary
infection) demonstrated an even higher in-hospi-
tal mortality rate, which might suggest that
colonisation should be considered as a potentially
important finding [83].
IA appears to be gaining a foothold in the ICU
in patients without classic risk-factors. In a large
study performed in a medical ICU, the investiga-
tors found microbiological or histopathological
evidence of Aspergillus infection in 6.7% of
patients; 64% were patients who did not have
an underlying haematological malignancy [83].
This observation has been confirmed in other
studies in ICUs [85]. Three ‘new’ risk-factors
stand out for IA: COPD, steroid use, and severe
hepatic failure. Even critically ill patients without
any risk-factor apart from a prolonged stay may
develop complex immunological derangements,
which put them at risk for developing IA.
Early identification of patients who require
antifungal therapy is very important and requires
diagnostic tools validated in the ICU population
that show positive results in an early phase of the
infection. Critical care physicians need a helpful
instrument to guide clinical practice in the ICU.
The clinical signs associated with IA are notori-
ously vague (fever, increased respiratory secre-
tions, high oxygen requirements, haemoptysis)
and lack specificity in the ICU. Mechanical ven-
tilation and atypical radiological abnormalities
(atelectasis, pleural effusions) preclude the use of
chest radiography as a helpful diagnostic tool for
the ICU patient. The halo sign on computed
tomography plays an important role in the neu-
tropenic patient early in the course of the disease.
Unfortunately, computed tomography in the ICU
patient is of little benefit, as no lesion specific for
IA has been identified in this population. Respi-
ratory cultures of Aspergillus take a minimum of
48 h to grow. Culture and direct microscopy of
respiratory samples have a sensitivity of approx-
imately 30% [84]. Although a positive culture
suggests that the patient has IA, it does not
discriminate between invasive forms and coloni-
sation. The positive predictive value varies,
depending on the degree of immunosuppression,
between 20% and 60% in non-neutropenic
patients [84].
Application of non-culture-based methods,
including galactomannan, PCR, and b-1–3D-glu-
can, may improve sensitivity, allowing an earlier
diagnosis to be made. The use of b-1–3D-glucan in
the ICU is hampered by its low positive predictive
value, because of false positivity associated with
other bacterial and fungal infections, the use of
albumin, and haemodialysis [84]. Thus far, no
prospective data on PCR detection are available
for ICU patients.
Treatment of IA is difficult and mortality
remains high, despite the introduction of new
antifungals [85]. A significantly better outcome
(response rate 52% vs. 30%) was demonstrated in
a randomised study that compared voriconazole
with conventional amphotericin B [86]. However,
86% of the patients were treated for a haemato-
logical malignancy, and no definite conclusions
Table 5. In-vitro susceptibility of Aspergillus spp. and
moulds to several antifungal drugsa
Species AMB ITR VOR POS CAS
A. fumigatus S S S S S-R
A. flavus S S S-R S S-R
A. terreus S-R S S S S
A. niger S S S S S
Mucor sp. S-R S-R R S-R R
Rhizopus sp. S S-R R S-R R
R, resistant; S, susceptible; AMB, amphotericin B; ITR,
itraconazole; VOR, voriconazole; POS, posaconazole; CAS,
cancidas.
aData adapted from references [90,117,118,125].
No breakpoints are established for Aspergillus sp. and
moulds. For the purposes of this table, susceptibility is
defined as £2 mg ⁄L for all drugs tested.
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can be drawn for the ICU population. In addition,
many aspects of antifungal therapy that are
relevant to the ICU population have not been
sufficiently addressed, including the pharmaco-
kinetic profile in patients with underlying renal
and hepatic dysfunction, interactions with fre-
quently used ‘ICU’ drugs, the best route of
administration, and the value of plasma level
monitoring.
In an era of increased availability of new
immunosuppressive drugs and better intensive
care, with prolonged survival, we can expect to
see a continuing increase in the incidence of IA.
Important questions remain. Is the incidence of IA
in one medical ICU in the same order of magni-
tude as in other ICUs (surgical, mixed)? Can the
delineation of patients at risk be improved? Is, for
instance, a hydrocortisone infusion of 7 days
enough for Aspergillus conidia to germinate and
to cause invasive disease? Do non-culture-based
methods applied to respiratory samples lead to an
early diagnosis and a potential survival advan-
tage in the ICU? Diagnostic techniques should be
interpreted with caution and should preferably be
validated against post-mortem findings, because
proven cases offer the most valuable information.
Finally, the results from trials of combination
antifungal therapy are eagerly awaited.
From the existing literature, the key learning
point is that ICU physicians should be alerted to
the possibility of IA in a mechanically ventilated
patient at risk with unexplained pulmonary infil-
trates.
Filamentous fungi—beyond Aspergillus
The last decade has witnessed the emergence of
new opportunistic pathogens, including Zygomy-
cetes, Fusarium spp., Paecilomyces spp., Scedospori-
um spp., and the dematiaceous fungi (e.g.,
Alternaria spp.) [1,87,88]. Some centres face a
tremendous increase in the number of infections
due to Zygomycetes. Mucor spp., Rhizopus spp.,
Rhizomucor spp., Absidia spp. and Cunninghamella
spp. are known to cause diseases [89–92]. These
pathogens are resistant to voriconazole and
caspofungin in vitro and in vivo.
Fusarium spp., Alternaria spp. and Scedosporium
spp. also account for mould infections among
solid-organ transplant recipients, with a crude
mortality rate of 90% for Scedosporium prolificans
and 55% for Scedosporium apiospermum [87,88].
S. apiospermum strains are typically susceptible to
the azoles, and S. prolificans strains tend to be
resistant to various antifungal agents. Other
agents of hyalohyphomycosis include Acremo-
nium, Paecilomyces, Penicillium, Scopulariopsis and
Trichoderma [87,88].
Acremonium
Fungi of the genus Acremonium are environmental
saprophytes, found in the soil and decaying plant
material, and are rarely human pathogens. In
immunocompetent individuals, Acremonium spp.
mainly cause foot mycetomas or corneal infec-
tions after inoculation during penetrating injuries.
Acremonium spp. are being increasingly recogni-
sed as opportunistic pathogens. It appears that
the major predisposing factors comprise pro-
longed use of corticosteroids, splenectomy and
bone marrow transplantation, along with subse-
quent tacrolimus administration.
At least 35 Acremonium infections in adults
have been described in the literature [87]. Fifteen
cases of documented Acremonium infection
(excluding mycetoma and keratitis) in children
have been reported [93]. In the recent reports, in
both children and adults, Acremonium strictum is
the most commonly identified species. The pres-
ence of adventitious forms of A. strictum provides
a mechanism for haematological spread and
dissemination of infection. Fungaemias caused
by A. strictum have been reported mainly in
neutropenic patients [87].
Paecilomyces
Paecilomyces is a cosmopolitan filamentous fungus
which inhabits the soil, decaying plants, and food
products. Some species of Paecilomyces are iso-
lated from insects. Paecilomyces is usually consid-
ered to be a contaminant but may also cause
infections in humans and animals. The genus
Paecilomyces contains several species. The most
common are Paecilomyces lilacinus and Paecilomy-
ces variotii.
P. lilacinus is an emerging pathogen that causes
severe human infections, including devastating
oculomycosis [94]. Usually, it shows low suscep-
tibility to conventional antifungal drugs in vitro,
and variable susceptibility to novel triazoles. A
review of the published literature identified 119
reported cases of human infection by P. lilacinus
between 1964 and 2004. Most were cases of
oculomycosis (51.3%), followed by cutaneous
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and subcutaneous infections (35.3%), and a
smaller group of miscellaneous infections
(13.4%). Direct cutaneous inoculation may lead
to these infections, which may involve almost any
organ or system of the human body; soft-tissue,
pulmonary and cutaneous infections, cellulitis,
onychomycosis, otitis media, endocarditis, osteo-
myelitis and catheter-related fungaemia have all
been reported [94]. Peritonitis and sinusitis are the
most common infections caused by P. variotii.
Lens implantation is the most frequent predis-
posing factor for oculomycosis. Cutaneous and
subcutaneous infections occur mainly in solid-
organ and bone marrow transplant recipients,
although surgery and primary or acquired immu-
nodeficiency are also relevant predisposing fac-
tors. Infections in apparently immunocompetent
patients have also been reported.
Surgical debridement combined with antifun-
gal drug therapy, or the correction of predispos-
ing factors, such as neutropenia, is usually
required to obtain improvement. Treatment with
traditional antifungal drugs often fails. Vorico-
nazole has demonstrated good activity in both
cutaneous and ocular infections in the few cases
in which this drug has been used. The new
triazoles ravuconazole and posaconazole show
good in-vitro activity against P. lilacinus and
could be promising therapeutic alternatives.
Caspofungin and terbinafine appear to be active
in vitro against P. variotii. Paecilomyces spp. do not
appear to be sensitive to fluconazole.
A report of P. lilacinus infection in a liver
transplant patient serves as an illustrative case
of infection caused by this mould [95]. A 56-year-
old male who was 12 months post-liver trans-
plant presented with a 2-month history of painful,
erythematous nodules over the right knee. Several
biopsies yielded a mould that was initially phe-
notypically identified as a Penicillium species, but
molecular sequence analysis ultimately deter-
mined the identity as P. lilacinus. Several courses
of oral voriconazole were required for resolution
of the infection. Skin and soft-tissue infections
were the most common presentation. This case
highlights the fact that treatment of Paecilomyces
infections may require multiple courses of anti-
fungal therapy, often with surgical debridement.
On the basis of their experience, the authors
suggest that voriconazole may be a useful treat-
ment alternative to the more traditional therapy
with amphotericin B-based agents.
Scedosporium
S. apiospermum is a significant opportunist with
very high levels of antifungal resistance [96].
Previously, it was mainly known to be involved in
traumatic, subcutaneous infections and in asymp-
tomatic pulmonary colonisation, but in recent
years, new disease entities have emerged. The
fungus has now become recognised as a potent
aetiological agent of severe infections in immu-
nocompromised patients. Currently, Scedosporium
infections are among the most common deep
mould infections. With a frequency of about 9%,
S. apiospermum is among the most common fila-
mentous fungi colonising the lungs of CF patients.
The intrinsic clinical potency of S. apiospermum
can be deduced from its extremely infrequent
isolation from outside and indoor air but its high
prevalence in the lungs of susceptible patients.
The natural environmental habitat of the fungus
is unknown; nutrient-rich, brackish waters such
as river estuaries have been suggested. The
fungus is strongly promoted by agricultural and,
particularly, by industrial pollution.
S. apiospermum has been specifically listed as an
important cause of death in transplant recipients,
with a frequency of one per 1000 patients [97]. A
comparable frequency (0.4%) has been observed
in patients with haematological malignancies [97].
The role of S. apiospermum in fatal infections may
be underestimated, due to the lack of accurate
diagnosis.
S. apiospermum is common in temperate cli-
mates and is less frequently encountered in the
tropics. Its natural niche is not known; all envi-
ronments from which it is currently isolated are
strongly influenced by human activity. It is a
eutrophic fungus that is commonly found in soil.
Its occurrence is promoted in manure-enriched or
polluted environments, such as agricultural land,
garden soil, sewer or ditch mud and polluted
pond bottoms. It is also found in hydrocarbon-
contaminated soils, being able to assimilate nat-
ural gas and aromatic compounds, and it has
therefore been suggested for use in bioremedia-
tion.
Diagnosis is achieved with a combination of
direct microscopy, histopathology, culture, radi-
ology and serology. Numerous studies have
shown that antifungal drugs such as amphoteri-
cin B, itraconazole, flucytosine, fluconazole and
terbinafine show low in-vitro activity against
S. apiospermum; however, some studies have
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demonstrated that itraconazole does have some
activity. The new triazoles are promising: voric-
onazole and ravuconazole appear to be active, but
posaconazole has shown variable activity. The in-
vitro activity of echinocandins against S. apiosper-
mum has generally been considered to be modest.
However, it is important to exercise caution in
interpreting in-vitro susceptibility results, because
clinical improvement of S. apiospermum infec-
tions with amphotericin B treatment has been
reported despite apparent in-vitro resistance to
this drug.
A major problem in recognition of S. apiosper-
mum infections is the fact that the fungus is a
typical opportunist. Therefore, none of the clinical
entities is fully characteristic for the species. Three
basic clinical syndromes can be distinguished
[96]: (i) localised disease after trauma; (ii) largely
asymptomatic or symptomatic colonisation of the
cavities; and (iii) systemic invasive disease. Trau-
matic infections are found in otherwise healthy
persons. Pulmonary infections are observed in
patients with predisposing pulmonary disorders.
Systemic disease occurs if the immune status of
the patient is severely impaired and in victims of
near-drowning. The fungus then shows marked
neurotropic behaviour. Secondary cutaneous
manifestations are infrequent with severe dissem-
ination. S. apiospermum has long been considered
to be a coloniser of the lungs of patients with
pulmonary disorders, but its consistent occur-
rence in the lungs of patients with CF has only
recently received proper attention [96]. The isola-
tion of S. apiospermum from the lungs of patients
with CF is remarkable, given its infrequent
isolation from indoor air, although there appear
to be regional differences.
S. apiospermum is increasingly recognised as an
important opportunistic pathogen in transplant
recipients [97]. Infection is associated with a high
rate of dissemination and poor outcome overall.
The authors carried out a retrospective analysis of
the Cleveland Clinic lung transplant database and
identified five patients with S. apiospermum iso-
lated from respiratory tract specimens. Dissemi-
nated disease developed in three patients,
whereas two appeared to be only colonised. This
report and the authors’ review of the literature
highlight the importance of early diagnosis and
differentiation from Aspergillus, since Scedospori-
um is inherently resistant to amphotericin B.
Effective therapeutic approaches being explored
include combinations of antifungals, because even
the newer triazoles have a 50% response rate in
clinical studies. Surgical debridement and im-
mune recovery are associated with improved
prognosis, favouring the use of agents that expe-
dite immune reconstitution in these patients.
Close monitoring of clinical improvement and
frequent re-evaluation of treatment is essential.
In conclusion, S. apiospermum appears to be a
truly emerging environmental pathogen and to
display a remarkable shift in its clinical spec-
trum. For an in-depth review of all aspects of
S. apiospermum, see the exhaustive review by
Guarro et al. [96] and the website of a joint
European Confederation of Medical Mycology
societies and the International Society for
Human and Animal Mycology Working Group
on Pseudallesheria–Scedosporium: http://www.
scedosporium-ecmm.com.
Scopulariopsis
Scopulariopsis brevicaulis is a rare and emerging
pathogen that has been increasingly reported in
the past two decades as a cause of deep mycosis
in hosts presenting with factors that predispose
them to infection [87]. S. brevicaulis and other
Scopulariopsis spp. have mainly been associated
with onychomycosis, but their spectrum of hu-
man infections includes post-traumatic keratitis
and endophthalmitis, disseminated skin lesions
and meningitis in AIDS patients, endocarditis
related to valvuloplasty or prosthetic valves,
subcutaneous hyalohyphomycosis in immuno-
compromised hosts, fungus ball and pneumonia,
and disseminated infections in stem-cell trans-
plant patients or hosts with leukaemia.
S. brevicaulis has been reported to be resistant
in vitro to amphotericin B, flucytosine, terbina-
fine, and azole compounds. Invasive infections
due to S. brevicaulis are unlikely to respond to a
particular antifungal treatment, and several ther-
apeutic approaches have been considered, such as
debridement or excision of necrotic tissue plus
chemotherapy, prolonged monotherapy with
azole agents or terbinafine, and combinations of
antifungal agents. The combined activity in vitro
of antifungal agents against S. brevicaulis has not
been assessed until recently. One study describes
the activities of ten combinations of antifungal
compounds against clinical isolates of this species
[98]. An unexceptional effect was observed for all
combinations. Synergy was observed for some
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isolates and combinations, particularly with
posaconazole–terbinafine (68% of strains), ampho-
tericin B–caspofungin (60%), and posaconazole–
caspofungin (48%).
Trichoderma
Trichoderma spp. are common, soil-borne, fila-
mentous fungi and have long been known as
non-harmful microorganisms. They are used in
biotechnology as sources of enzymes and antibi-
otics. Moreover, they are applied to agricultural
crops as plant growth promoters and biofungi-
cides. However, as recently emerging fungal
pathogens, Trichoderma strains have been detected
on the skin, in the lung and as causative agents of
peritonitis in peritoneal dialysis patients, and
have been found to be disseminated in the liver,
brain, heart and stomach of immunocompro-
mised patients [2]. The majority of the pathogenic
Trichoderma isolates are members of the species
Trichoderma longibrachiatum. Despite systemic
antifungal therapy, the prognosis for Trichoderma
infection is poor, regardless of the type of infec-
tion and the therapy used.
Agents of mucormycosis (zygomycosis)
The Mucorales are opportunistic fungi capable
of causing acute, rapidly developing and often
fulminant infections in the compromised host.
Infections are thought to be acquired by
inhalation or by progression of previously local-
ised cutaneous lesions, and occur in patients
with neutropenia. Several recent reviews and
commentaries underline the increasing preva-
lence and awareness of these infections
[19,89,91,92]. The spectrum of zygomycosis is
reviewed here.
Zygomycetes may also cause lethal infections in
patients with diabetes, patients receiving deferox-
amine therapy, injection drug users, and patients
with no apparent immune impairment. Invasive
zygomycosis is clinically similar to aspergillosis;
fungi commonly affect the paranasal sinuses
(39%), the lungs (24%), and the skin (19%).
Dissemination develops in 23% of cases and the
mortality rate is 96%; risk-factors are shown in
Table 4.
Major risk-factors include ketoacidosis in
untreated type 1 diabetes mellitus, lymphoma,
leukaemia, neutropenia, corticosteroid or other
long-term immunosuppressive therapies, and
deferoxamine therapy of dialysis patients with
aluminium or iron overload. To date, there are
only a few reported infections associated with
AIDS, so AIDS does not appear to be a significant
risk-factor. Trauma to the skin, including severe
burns, intravenous catheters, intravenous drug
abuse, or even an insect bite, may also result in
infection in the immunocompetent host.
The pathogenesis of mucormycosis is unclear,
and while it is undoubtedly exogenous, possible
sources of infection have only occasionally been
suggested, e.g., adhesive dressings, air-condition-
ing filter units, and food. Cutaneous trauma may
be an underestimated event in the initiation of
many cases of mucormycosis. However, most
infections follow inhalation of spores that have
been released into the air, and the lungs and nasal
sinuses are common sites of infection. The most
common predisposing illness for gastrointestinal
infection is severe malnutrition or disruption of
the gastrointestinal mucosa.
The infectious propagule responsible for the
establishment of zygomycosis is unproven. Many
studies have suggested that sporangiospores are
responsible, while others have indicated that
small hyphal fragements initiate disease. Since
sporangiospores of mucoraceous fungi are
uncommon in air and are readily contained by
phagocytic cells normally found in pulmonary
tissues, it is possible that in some cases, especially
where trauma is the associated factor, hyphal
fragments are the infectious propagules.
Mucormycosis is distributed worldwide. Many
different organisms have been implicated, but the
most common causes of human infection, listed in
order of apparent incidence, are Rhizopus oryzae
and Rhizopus microsporus var. rhizopodiformis.
Other less frequent aetiological agents, but for
which a major pathogenic role in humans has
been established, include Absidia corymbifera, Apo-
physomyces elegans, Cunninghamella bertholletiae,
Mucor spp., Rhizomucor pusillus and Saksenaea
vasiformis. These moulds are ubiquitous, are
thermotolerant and can be isolated in large
numbers from soil or decomposing organic mat-
ter, such as fruit and bread. Their spores can often
be found in the outside air. Nosocomial outbreaks
of mucormycosis are not as common as hospital-
related Aspergillus infections, but have been
reported in leukaemic patients. Nosocomial cuta-
neous infections with R. microsporus var. rhizopod-
iformis have been traced to contaminated
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dressings and wooden tongue depressors used as
immobilising splints in a neonatal ICU. The major
risk-factors predisposing individuals to muco-
rmycosis include uncontrolled diabetes mellitus,
other forms of metabolic acidosis, burns and
malignant haematological disorders. Treatment
is seldom of benefit unless these underlying
conditions can be corrected.
In most cases, mucormycoses occur in patients
already receiving treatment because of another
disease. For precisely this reason, they may not be
immediately recognised. The clinical hallmark of
mucormycosis is vascular invasion resulting in
thrombosis and tissue infarction ⁄necrosis. In most
cases, the infection is relentlessly progressive and
results in death unless treatment with a combi-
nation of surgical debridement and antifungal
therapy is initiated promptly.
Mucormycosis is an opportunistic infection and
is seldom seen in normal persons. Various forms
are recognised, each of which is associated with
particular underlying conditions. Like the aetio-
logical agents of aspergillosis, the causal organ-
isms of mucormycosis have a predilection for
vascular invasion, causing thrombosis, infarction
and necrosis of tissue. The anatomical distribution
of lesions appears to correlate to a certain degree
with defined predisposing conditions, e.g., cra-
niofacial involvement in individuals with diabetic
acidosis, pulmonary and disseminated infection
in patients with acute leukaemia, and gastroin-
testinal and cutaneous lesions following local
trauma. Indeed, cutaneous infections have possi-
bly replaced craniofacial and pulmonary disease
as the prevalent clinical manifestation of muco-
rmycosis, a change mirrored by the emergence of
R. microsporus var. rhizopodiformis (as R. rhizopod-
iformis in many cases) as a significant pathogen.
Zygomycetes appear to be susceptible to
amphotericin B and are generally not susceptible
to the triazoles and echinocandins (Table 5) [99].
Among the extended-spectrum triazoles, posaco-
nazole appears to be active against most of the
Zygomycetes [100,101].
Rhinocerebral mucormycosis
The terms rhinocerebral and craniofacial mucor-
mycosis are used to describe infection that begins
in the paranasal sinuses and then spreads to
involve the orbit, face, palate or brain. The term
should be used only when there is documented
brain involvement in addition to involvement of
sinuses alone or to involvement of both sinuses
and orbit respectively. It is not clear whether
paranasal and rhinorobital mucormycosis are
simply rhinocerebral mucormycosis in evolution
or whether the extent to which mucormycosis
progresses beyond the paranasal sinuses to
involve the orbit and brain is dependent on the
host response. Several recent case series and
reviews describe a clinical variety of rhinocerebral
mucormycosis termed rhino–orbital–cerebral mu-
cormycosis. Nasal endoscopy appears to be useful
in diagnosis, tissue debridement and follow-up of
patients.
Rhinocerebral mucormycosis is most com-
monly seen in acidotic individuals, particularly
those with uncontrolled diabetes mellitus, but it
also occurs in leukaemic patients and organ
transplant recipients. It is the most common
clinical form of mucormycosis and is often fatal
within a week of onset if left untreated. It is
assumed that the initial event is colonisation of
the nasal mucosa, allowing the fungus to spread
via the paranasal sinuses into the orbit. Involve-
ment of the brain and cavernous sinus occurs by
way of the orbital apex. Multiple approaches to
treatment are required. Early clinical and labora-
tory diagnosis is crucial. If the infection spreads
into the palate, a black necrotic lesion is often
found. This is an important diagnostic sign, and
necrotic lesions may also be found on the nasal
mucosa. Nasal septum or palatal perforation is
frequent. Drainage of black pus from the eye is an
ominous but useful diagnostic sign. From the
orbit, infection may spread into the brain, leading
to frontal lobe necrosis and abscess formation.
These features result from invasion of the fungus
through the cribiform plate of the ethmoid bone.
The cerebrospinal fluid (CSF) findings are non-
specific. CSF cultures are sterile.
The radiological findings are non-specific, but
are useful in delineating the extent of the infec-
tion.
Pulmonary mucormycosis
Pulmonary mucormycosis is seldom diagnosed
during life. Mucormycosis may develop in the
lungs as a result of aspiration of infectious
material, or following inhalation, or from hae-
matogenous or lymphatic spread during dissem-
ination. Most cases occur in leukaemic patients
undergoing remission induction treatment. Pul-
monary infiltrates develop with infarction of focal
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areas of lung. The clinical signs are those of
bronchitis, pneumonia, and thrombosis. There is
necrosis of the parenchyma, leading to cavitation;
the bronchi may be perforated, resulting in
haemoptysis. If untreated, haematogenous dis-
semination to other organs, particularly the brain,
will often occur. There are no characteristic
symptoms or signs to distinguish mucormycosis
from aspergillosis. The infection is fatal within 2–
3 weeks.
Clinicinans are aware that pulmonary zygomy-
cosis is being seen more frequently in patients
with cancer. However, the clinical manifestation
is similar to that of invasive pulmonary aspergil-
losis. Computed tomography imaging could
potentially differentiate the two infections. Most
cases of pulmonary zygomycosis in these patients
appear to develop as breakthrough infections if
treatment with antifungal agents effective against
Aspergillus spp. is administered.
Cutaneous mucormycosis
Cutaneous mucormycosis is a particular problem
in infected patients with burns, in whom spread
to underlying tissue is common. The initial signs
include fever, swelling and changes in the
appearance of the burn wound. The development
of severe underlying necrosis and infarction in a
burn should suggest the diagnosis.
Cutaneous infections account for 16% of all
forms of zygomycosis, with an associated mortal-
ity rate of 16%, as compared to 67% for rhinoce-
rebral, 83% for pulmonary and 100% for
disseminated infection. The most common caus-
ative organisms are Rhizopus spp., although oth-
ers, such as Mucor and Absidia, are also frequently
seen, whereas S. vasiformis and A. elegans are rare
pathogens. Cutaneous zygomycosis is less likely
to be associated with severe systemic illness than
are other forms, while local predisposing factors
such as burn, trauma, surgery, needlesticks and
others play a major role. The most common sites
involved in cutaneous zygomycosis are the lower
and upper extremities, followed by the head and
neck, and then the abdomen.
Mucormycotic gangrenous cellulitis can follow
other forms of trauma to the skin. In diabetic or
immunosuppressed patients, cutaneous lesions
may arise at an insulin injection site or a catheter
insertion site. More massive trauma, such as open
fractures or crash injuries, has been seen in other
patients. Necrotising cutaneous mucormycosis
has occurred in patients who have had contam-
inated surgical dressings applied to their skin.
Infections have also been described in a variety of
individuals after traumatic injury or near-drown-
ing. The most recent examples of zygomycosis in
trauma patients are exemplified by survivors of
the tsunami in Southeast Asia on 26 December
2004.
Disseminated mucormycosis
Disseminated mucormycosis may follow any of
the four forms of mucormycosis described so
far, but it is usually seen in neutropenic patients
with pulmonary infection. Less commonly,
dissemination occurs from the gastrointestinal
tract, or from burns or other cutaneous lesions.
The most common site of spread is the brain,
but metastatic necrotic lesions have also been
found in the spleen, heart and other organs.
Zygomycetes can complicate peritoneal dialysis.
Disseminated mucormycosis is usually diag-
nosed after the patient has died of the infection.
Occasionally, metastatic cutaneous lesions permit
an earlier diagnosis.
Cerebral infection following haematogenous
dissemination is distinct from the rhinocerebral
form of mucormycosis. It results in abscess
formation and infarction. Patients present with
sudden onset of focal neurological deficits or
coma. Investigation of the CSF is unhelpful:
protein, glucose and cell abnormalities are non-
specific, and cultures are sterile. Computed
tomography and magnetic resonance scans are
useful in locating the lesions.
Mucormycosis in AIDS
Mucormycosis in cases of HIV disease is rare.
However, it can be the presenting opportunistic
infection in AIDS. Predisposing factors for muco-
rmycosis in HIV disease include low CD4 count,
neutropenia, and active intravenous drug use.
Mucormycosis can present in the basal ganglia,
the skin, the gastrointestinal tract, or the respira-
tory tract, or may be disseminated.
Mucormycosis in haematological malignancies
The incidence of mucormycosis in patients with
haematological malignancies has increased dur-
ing the last decade, probably due to the more
severe and prolonged post-chemotherapy neutro-
penia. The diagnosis is usually made at autopsy,
and its incidence in autopsy studies in patients
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with haematologic malignancies ranges between
0.4% and 0.9%. Several retrospective studies have
been published [102].
Voriconazole is increasingly used as prophy-
laxis in patients with haematological malignan-
cies. Several reports have linked the prolonged
use of this agent to an increase in infections
caused by Zygomycetes [103–105]. However, an
increase in zygomycosis was reported before the
availability of voriconazole [106].
Mucormycosis in solid-organ transplant recipients
Mucormycosis is a rare infection in renal trans-
plant recipients; however, mortality is exceed-
ingly high. Risk-factors predisposing to this
disease include prolonged neutropenia, diabetes,
and immunosuppression. Mucormycosis is a rare
but highly invasive infection following orthotopic
liver transplantation.
CHANGING EPIDEMIOLOGY AND
IMPLICATIONS FOR THERAPY
The epidemiology of invasive fungal infections in
immunocompromised patients is rapidly chang-
ing. Factors that influence the current trends in
the epidemiology of opportunistic fungal infec-
tions are given in Table 6. Recognition of these
epidemiological changes is critical to patient care.
Key elements in the selection of the appropriate
antifungal agent are the type of patient (solid-
organ or stem-cell transplant), severity of immu-
nosuppression, history of prolonged exposure to
antifungal drugs, and knowledge of the genera
and species of the infecting pathogen and its
typical susceptibility pattern.
More than 17 different species of Candida have
been identified as aetiological agents of BSIs and
other manifestations of systemic candidosis.
About 95% of candidaemia cases are caused by
four species: C. albicans, C. glabrata, C. parapsilosis,
and C. tropicalis [2]. The excellent activities of new
and established systemic antifungal agents
against C. albicans, C. parapsilosis and C. tropicalis
are well-documented. Among these common
species, only C. glabrata can be said to be truly
emerging as a cause of candidaemia, due in part
to its intrinsic and acquired resistance to azoles
and other commonly used antifungal agents. The
remaining 5% of candidaemias are caused by 12–
14 different species. Of note is the emergence of
Candida dubliniensis in some centres [107].
Although these species must be considered as
rare causes of BSIs, several have been observed to
occur in nosocomial clusters and ⁄ or to exhibit
innate or acquired resistance to one or more
established antifungal agents. Given that these
uncommon species may emerge as important
opportunistic pathogens in the future, it is imper-
ative that an accurate diagnosis and identification
of the fungal pathogen is made. Furthermore, it is
useful to keep in mind that broad and injudicious
use of any anti-infective agent in severely immu-
nocompromised hosts may result in superinfec-
tions due to organisms that are both unusual and
drug-resistant.
It is evident that there has been an increase in
rare mould infections in recent decades [108].
These infections have been reported primarily in
severely immunocompromised patients. The
emergence of these organisms is multifactorial
and can be related to more intense immunosup-
pression, the prolonged survival of patients who
have what were previously fatal diseases, and the
selective pressure of broad-spectrum antifungal
agents used for prophylaxis or therapy. Among
the organisms causing these rare mould infec-
tions, the Zygomycetes are the most commonly
encountered, and in some institutions, the
increase in the incidence of these organisms
appears to be associated with the use of vorico-
nazole. A. terreus, a species that is resistant to
amphotericin B, and less frequently, Aspergillus
ustus and A. lentulus, have been noted increas-
ingly as causes of invasive aspergillosis in ter-
tiary-care centres in the US. Several species of
Scedosporium with innate resistance to many anti-
fungal agents have emerged as major causes of
Table 6. Variables that account for the current trends in
the epidemiology of opportunistic fungal infectionsa
Increasing number of susceptible hosts: transplant type
Centre-to-centre differences: patient selection
Greater laboratory expertise in detection and identification
of fungi
Use of new transplant modalities for haematopoietic
stem-cell transplantation
Changing surgical techniques: evolution in organ
transplant practices
Use of corticosteroid-sparing regimens and overall
conservative approach to immunosuppression
Use of novel immunosuppressive agents
Antimicrobial prophylactic practices
Exposure to azoles
Better control of underlying diseases
aData compiled from reference [110].
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disseminated mould infections that are frequently
very difficult to treat. Among patients who have
haematological malignancies, are neutropenic or
have received a haematopoietic stem-cell trans-
plant, infections due to Fusarium spp. respond
poorly to many antifungal agents. Dematiaceous,
or brown–black fungi, most often associated with
chronic localised infections, are now increasingly
reported as a cause of disseminated infection in
immunosuppressed hosts. Concomitant with the
increased number of infections due to these rare
moulds, several new mould-active antifungal
agents have been developed. The new ex-
panded-spectrum azole voriconazole has changed
our approach to moulds such as S. apiospermum,
Fusarium spp. and A. terreus that are amphoteri-
cin B-resistant. Posaconazole, the most recently
approved expanded-spectrum azole, is the first
drug in the azole class to show activity against the
Zygomycetes and has proven extremely useful for
step-down therapy after initial treatment with
amphotericin B. It is not known whether posaco-
nazole is effective as primary therapy for zygo-
mycosis; the use of this agent for that purpose
awaits clinical trials with the recently developed
intravenous formulation of posaconazole.
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